Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2010

01-06-2010 | Brief report

Acceptability of a Non-Woven Device for Vaginal Drug Delivery of Microbicides or Other Active Agents

Authors: Carol L. Joanis, Catherine W. Hart

Published in: AIDS and Behavior | Issue 3/2010

Login to get access

Abstract

Vaginal microbicides could reduce incidence of HIV. However, the current method of delivering gel formulations (standard applicator) can result in acceptability concerns/issues. This study evaluated the concept of using a non-woven textile material (modified tampon) for vaginal drug delivery. The study was nested within a Phase I randomized safety trial of lime juice concentrations used intra-vaginally. Of 47 women completing the safety trial, 16 were interviewed about their experiences. Overall, women found the concept of non-woven materials for vaginal drug delivery acceptable for use in delivering yeast medications (13 of 16) and STI/HIV preventives (10 of 16).
Literature
1.
2.
Moench TR, Chipato T, Padian NS, et al. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS. 2001;15(13):1595–602.CrossRefPubMed
3.
Family Health International’s Quarterly Health Bulletin Network. User, partner attitudes influence barrier use: scientists examine how and why couples use barrier methods, and what they like or do not like about them. Network 2000. 2000;20(2):1.
4.
Coggins C, Blanchard K, Alvarez F, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2000;76(6):480–3.CrossRefPubMed
5.
Barnhart KT, Pretorius ES, Shaunik A, Timbers KT, Nasution M, Mauck C. Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 ml and 3.5 ml). Contraception. 2005;72(1):65–70.CrossRefPubMed
6.
Padian NS, van der Straten A, Ramjee G, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251–61.CrossRefPubMed
7.
Mauck CK, Ballagh SA, Creinin MD, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr. 2008;49(3):243–50.CrossRefPubMed
8.
Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. J Womens Health (Larchmt). 2007;16(7):1041–51.CrossRef
9.
Pool R, Hart G, Green G, Harrison S, Nyanzi S, Whitworth J. Men’s attitudes to condoms and female controlled means of protection against HIV and STDs in south-western Uganda. Cult Health Sex. 2000;2(2):197–211.CrossRefPubMed
10.
Potts M. The urgent need for a vaginal microbicide in the prevention of HIV transmission. Am J Public Health. 1994;84(6):890–1.CrossRefPubMed
11.
Geonnotti AR, Peters JJ, Katz DF. Erosion of microbicide formulation coating layers: effects of contact and shearing with vaginal fluid or semen. J Pharm Sci. 2005;94(8):1705–12.CrossRefPubMed
Metadata
Title
Acceptability of a Non-Woven Device for Vaginal Drug Delivery of Microbicides or Other Active Agents
Authors
Carol L. Joanis
Catherine W. Hart
Publication date
01-06-2010
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2010
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-009-9655-6

Other articles of this Issue 3/2010

AIDS and Behavior 3/2010 Go to the issue

Original Paper

Using Electronic Drug Monitor Feedback to Improve Adherence to Antiretroviral Therapy Among HIV-Positive Patients in China

Original Paper

Provider-related Barriers to Rapid HIV Testing in U.S. Urban Non-profit Community Clinics, Community-based Organizations (CBOs) and Hospitals

Original Paper

A Randomized Controlled Trial of an HIV Prevention Intervention for Street-Based Female Sex Workers in Yerevan, Armenia: Preliminary Evidence of Efficacy

Original Paper

Vaginal Practices and Associations with Barrier Methods and Gel Use Among Sub-Saharan African Women Enrolled in an HIV Prevention Trial

Original Paper

Acceptability of UC781 Gel as a Rectal Microbicide Among HIV-Uninfected Women and Men

Original Paper

Efficacy of a Single-Session HIV Prevention Intervention for Black Women: A Group Randomized Controlled Trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits